In:
Pathology International, Wiley, Vol. 64, No. 12 ( 2014-12), p. 624-627
Abstract:
C rohn's disease is a chronic inflammatory bowel disease of unknown aetiology. Mucosal inflammatory dysregulation is likely important, with increased production of pro‐inflammatory cytokines, including tumour necrosis factor alpha ( TNF α). The chimeric monoclonal antibody, infliximab, inhibits TNF α and promotes intestinal mucosal healing. Despite this, many patients still require surgical intervention. Patients who have undergone colonic resection post‐infliximab therapy, show markedly variable morphological response to treatment. FOXP3 + CD4 + regulatory T ‐cells have been shown to have a protective role in autoimmune/inflammatory diseases and their sequestration to the bowel is found in those treated with infliximab. We examined the immunohistochemical profile of lymphoid aggregates in tissue sections from post‐infliximab C rohn's colitis resection specimens, classified as morphological responders or non‐responders, defined in relation to the absence/presence of mucosal ulceration and active inflammation, and a control group. Results indicated no significant diffences in CD68 ‐positive cell counts but increased FOXP3 ‐positive ( P = 0.02) and CD4 ‐positive ( P = 0.05) cell counts in responders versus non‐responders. Untreated control scores were similar to non‐responders. Although based on small study numbers, our results suggest an association between upregulation of FOXP3 +/ CD4 + regulatory T ‐cells and morphological response to infliximab therapy. This represents a possible quantitative methodology for monitoring therapeutic response to infliximab therapy, based on immunohistochemical evaluation of endoscopic biopsy specimens.
Type of Medium:
Online Resource
ISSN:
1320-5463
,
1440-1827
DOI:
10.1111/pin.2014.64.issue-12
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2008574-6
Permalink